Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

Abstract Background The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer. We compared the antitumor activity of Z-endoxifen with tamoxifen and letrozole in the letrozole-sensitive MCF7 aromatase express...

Full description

Bibliographic Details
Main Authors: Swaathi Jayaraman, Xiaonan Hou, Mary J. Kuffel, Vera J. Suman, Tanya L. Hoskin, Kathryn E. Reinicke, David G. Monroe, Krishna R. Kalari, Xiaojia Tang, Megan A. Zeldenrust, Jingfei Cheng, Elizabeth S. Bruinsma, Sarah A. Buhrow, Renee M. McGovern, Stephanie L. Safgren, Chad A. Walden, Jodi M. Carter, Joel M. Reid, James N. Ingle, Matthew M. Ames, John R. Hawse, Matthew P. Goetz
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Breast Cancer Research
Subjects:
Z-endoxifen
Tamoxifen
Tumor growth in vivo
Estrogen-regulated genes
AI-resistant and AI-sensitive ER+ breast cancer
Signaling kinase
Online Access:http://link.springer.com/article/10.1186/s13058-020-01286-7

Internet

http://link.springer.com/article/10.1186/s13058-020-01286-7

Similar Items